Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl. 2017;7:1–59.

Cannata-Andía JB, Martín-Carro B, Martín-Vírgala J, Rodríguez-Carrio J, Bande-Fernández JJ, Alonso-Montes C, et al. Chronic kidney disease—mineral and bone disorders: pathogenesis and management. Calcif Tissue Int [Internet]. 2021 [cited 2022 Aug 25];108:410–22. Available from: https://doi.org/10.1007/s00223-020-00777-1

Lalayiannis AD, Crabtree NJ, Ferro CJ, Askiti V, Mitsioni A, Biassoni L, et al. Routine serum biomarkers, but not dual-energy X-ray absorptiometry, correlate with cortical bone mineral density in children and young adults with chronic kidney disease. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2021;36:1872–81.

CAS  Google Scholar 

Klaus G, Watson A, Edefonti A, Fischbach M, Rönnholm K, Schaefer F, et al. Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol Berl Ger. 2006;21:151–9.

Article  CAS  Google Scholar 

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease–mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int [Internet]. 2017 [cited 2018 Oct 1];92:26–36. Available from: http://www.sciencedirect.com/science/article/pii/S0085253817302491

Hannan FM, Kallay E, Chang W, Brandi ML, Thakker RV. The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat Rev Endocrinol. 2018;15:33–51.

Article  PubMed  PubMed Central  Google Scholar 

Alexander ST, Hunter T, Walter S, Dong J, Maclean D, Baruch A, et al. Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol Pharmacol [Internet]. 2015 [cited 2018 May 6];88:853–65. Available from: http://molpharm.aspetjournals.org/content/88/5/853.

Chen P, Narayanan A, Wu B, Gisleskog PO, Gibbs JP, Chow AT, et al. Population pharmacokinetic and pharmacodynamic modeling of etelcalcetide in patients with chronic kidney disease and secondary hyperparathyroidism receiving hemodialysis. Clin Pharmacokinet. 2018;57:71–85.

Article  CAS  PubMed  Google Scholar 

Goodman WG, Hladik GA, Turner SA, Blaisdell PW, Goodkin DA, Liu W, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol JASN. 2002;13:1017–24.

Article  CAS  PubMed  Google Scholar 

Lindberg JS, Moe SM, Goodman WG, Coburn JW, Sprague SM, Liu W, et al. The Calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism. Kidney Int. 2003;63:248–54.

Article  CAS  PubMed  Google Scholar 

Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, et al. The Calcimimetic AMG 073 as a Potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol [Internet]. American Society of Nephrology; 2003 [cited 2022 Sep 18];14:575–83. Available from: http://jasn.asnjournals.org/content/14/3/575

Block GA, Martin KJ, de Francisco ALM, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–25. RCT which reported benefic effects of cinacalcet on PTH.

Article  CAS  PubMed  Google Scholar 

Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, et al. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J Am Soc Nephrol JASN. 2005;16:800–7.

Article  CAS  PubMed  Google Scholar 

Messa P, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol CJASN. 2008;3:36–45.

Article  CAS  PubMed  Google Scholar 

Akiba T, Akizawa T, Tsukamoto Y, Uchida E, Iwasaki M, Koshikawa S, et al. Dose determination of cinacalcet hydrochloride in Japanese hemodialysis patients with secondary hyperparathyroidism. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2008;12:117–25.

CAS  Google Scholar 

Malluche HH, Monier-Faugere M-C, Wang G, Frazã OJM, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008;69:269–78.

Article  CAS  PubMed  Google Scholar 

Schaefer RM, Bover J, Dellanna F, Sanz D, Asensio C, Sánchez González MC, et al. Efficacy of cinacalcet administered with the first meal after dialysis: the SENSOR Study. Clin Nephrol. 2008;70:126–34.

Article  CAS  PubMed  Google Scholar 

Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2011;26:1327–39.

CAS  Google Scholar 

EVOLVE Trial Investigators, Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482–94. The EVOLVE trial randomizing 3883 hemodialysis patients to cinacalcet versus placebo demonstrated a clinical fracture risk reduction after adjustment.

Martin KJ, Bell G, Pickthorn K, Huang S, Vick A, Hodsman P, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2014;29:385–92.

CAS  Google Scholar 

Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Kidney Int [Internet]. 2014 [cited 2019 May 1];85:191–7. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0085253815561450

Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, et al. Effect of cinacalcet and vitamin D analogs on fibroblast growth factor-23 during the treatment of secondary hyperparathyroidism. Clin J Am Soc Nephrol CJASN. 2015;10:1021–30.

Article  CAS  PubMed  Google Scholar 

Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: the EVOLVE trial. Clin J Am Soc Nephrol CJASN. 2015;10:800–7.

Article  CAS  PubMed  Google Scholar 

Wetmore JB, Gurevich K, Sprague S, Da Roza G, Buerkert J, Reiner M, et al. A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol CJASN. 2015;10:1031–40.

Article  CAS  PubMed  Google Scholar 

Fukagawa M, Yokoyama K, Shigematsu T, Akiba T, Fujii A, Kuramoto T, et al. A phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of etelcalcetide (ONO-5163/AMG 416), a novel intravenous calcimimetic, for secondary hyperparathyroidism in Japanese haemodialysis patients. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2017;32:1723–30.

CAS  Google Scholar 

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317:156–64. RCT which reported noninferiority of etelcalcetide compared to cinacalcet in 343 patients.

Article  CAS  PubMed  Google Scholar 

Warady BA, Iles JN, Ariceta G, Dehmel B, Hidalgo G, Jiang X, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis. Pediatr Nephrol Berl Ger. 2019;34:475–86.

Article  Google Scholar 

Eddington H, Chinnadurai R, Alderson H, Ibrahim ST, Chrysochou C, Green D, et al. A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism. BMC Nephrol. 2021;22:106.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD. Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol CJASN. 2010;5:110–6.

Article  CAS  PubMed  Google Scholar 

Prié D. FGF23 and cardiovascular risk. Ann Endocrinol. 2021;82:141–3.

Article  Google Scholar 

Goodman WG, Ward DT, Martin KJ, Drayer D, Moore C, Xu J, et al. Activation of the calcium receptor by calcimimetic agents is preserved despite modest attenuating effects of hyperphosphatemia. J Am Soc Nephrol [Internet]. American Society of Nephrology; 2022 [cited 2022 Aug 28];33:201–12. Available from: http://jasn.asnjournals.org/content/33/1/201

Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, et al. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J Pharmacol Exp Ther [Internet]. 2013 [cited 2018 May 6];346:229–40. Available from: http://jpet.aspetjournals.org/content/346/2/229

Pereira L, Meng C, Marques D, Frazão JM.Old and new calcimimetics for treatment of secondary hyperparathyroidism: impact on biochemical and relevant clinical outcomes. Clin Kidney J [Internet]. 2018 [cited 2022 Aug 28];11:80–8. Available from.

Russo D, Tripepi R, Malberti F, Di Iorio B, Scognamiglio B, Di Lullo L, et al. Etelcalcetide in patients on hemodialysis with severe secondary hyperparathyroidism. Multicenter Study in “Real Life.” J Clin Med. 2019;8:E1066.

Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, et al. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308:627–35.

Article  CAS  PubMed  Google Scholar 

Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, et al. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Kidney Int [Internet]. 2005 [cited 2022 Aug 26];67:467–76. Available from: https://www.sciencedirect.com/science/article/pii/S008525381550481X

Kawata T, Imanishi Y, Kobayashi K, Onoda N, Okuno S, Takemoto Y, et al. Direct in vitro evidence of the suppressive effect of cinacalcet HCl on parathyroid hormone secretion in human parathyroid cells with pathologically reduced calcium-sensing receptor levels. J Bone Miner Metab. 2006;24:300–6.

Article  CAS  PubMed  Google Scholar 

Meola M, Petrucci I, Barsotti G. Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant [Internet]. 2009 [cited 2022 Oct 3];24:982–9. Available from: https://doi.org/10.1093/ndt/gfn654

Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006;109:339–65.

Article  CAS  PubMed  Google Scholar 

Ngamkam J, Vadcharavivad S, Areepium N, Auamnoy T, Takkavatakarn K, Katavetin P, et al. The impact of CASR A990G polymorphism in response to cinacalcet treatment in hemodialysis patients with secondary hyperparathyroidism. Sci Rep [Internet]. 2021 [cited 2022 Aug 27];11:18006. Available from: https://www.nature.com/articles/s41598-021-97587-8

Vezzoli G, Terranegra A, Arcidiacono T, Biasion R, Coviello D, Syren ML, et al. R990G polymorphism of calcium-sensing receptor does produce a gain-of-function and predispose to primary hypercalciuria. Kidney Int. 2007;71:1155–62.

Article  CAS  PubMed  Google Scholar 

Moe SM, Wetherill L, Decker BS, Lai D, Abdalla S, Long J, et al. Calcium-sensing receptor genotype and response to cinacalcet in patients undergoing hemodialysis. Clin J Am Soc Nephrol CJASN. 2017;12:1128–38.

Article  CAS  PubMed  Google Scholar 

Bernardor J, Flammier S, Salles J-P, Amouroux C, Castanet M, Lienhardt A, et al. Off-label use of cinacalcet in pediatric primary hyperparathyroidism: a French multicenter experience. Front Pediatr. 2022;10: 926986.

Article  PubMed  PubMed Central  Google Scholar 

Berger CE, Rathod H, Gillespie JI, Horrocks BR, Datta HK. Scanning electrochemical microscopy at the surface of bone-resorbing osteoclasts: evidence for steady-state disposal and intracellular functional compartmentalization of calcium. J Bone Miner Res Off J Am Soc Bone Miner Res. 2001;16:2092–102.

Article  CAS  Google Scholar 

Cianferotti L, Gomes AR, Fabbri S, Tanini A, Brandi ML. The calcium-sensing receptor in bone metabolism: from bench to bedside and back. Osteoporos Int [Internet]. 2015 [cited 2018 May 25];26:2055–71. Available from: http://link.springer.com/article/https://doi.org/10.1007/s00198-015-3203-1

Mentaverri R, Yano S, Chattopadhyay N, Petit L, Kifor O, Kamel S, et al. The calcium sensing receptor is directly involved in both osteoclast differentiation and apoptosis. FASEB J [Internet]. 2006 [cited 2017 Nov 14];20:2562–4. Available from: http://www.fasebj.org/content/20/14/2562

Nguyen-Yamamoto L, Bolivar I, Strugnell SA, Goltzman D. Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. J Am Soc Nephrol JASN. 2010;21:1713–23.

Article  CAS  PubMed